Simon Belenkiy, left, and Sulamif Belenkaya were given monoclonal antibodies to combat COVID-19. (Courtesy)
Illustrative: In this undated image from video provided by Regeneron Pharmaceuticals on Friday, October 2, 2020, scientists work with a bioreactor at a company facility in New York state, for efforts on an experimental coronavirus antibody drug. (Regeneron via AP)
This photo provided by Eli Lilly shows the drug bamlanivimab. On Monday, November 9, 2020, the Food and Drug Administration cleared emergency use of bamlanivimab, the first antibody drug to help the immune system fight COVID-19. The drug is for people 12 and older with mild or moderate COVID-19 not requiring hospitalization. (Courtesy of Eli Lilly via AP)
Share this article
TEL AVIV, Israel and RALEIGH, N.C., Jan. 28, 2021 /PRNewswire/
RedHill Biopharma Ltd. (Nasdaq: RDHL) ( RedHill or the Company ), a specialty biopharmaceutical company, today announced a manufacturing agreement with Cosmo Pharmaceuticals NV (SIX: COPN) ( Cosmo ) to further expand manufacturing capacity for opaganib (Yeliva
®, ABC294640)
[1], to address prospective demand subsequent to potential global emergency use authorizations. The growing concerns over viral mutations and the spread of new potent and evasive viral strains have increased the dire need for new COVID-19 therapeutics,
said Reza Fathi, PhD., RedHill s Senior VP, R&D. We are very pleased to expand the manufacturing capacity of opaganib with a partner of Cosmo s quality. Opaganib is designed to act broadly against different viral strains irrespective of mutations in the Spike protein. Opaganib is a Phase 2/3-stage novel, orally-administered sphingosine kinase-2 (SK2) inhibitor with dem
Credit: RedHill Biopharma
New agreement further expands manufacturing capacity for orally-administered opaganib following positive top-line data from its Phase 2 COVID-19 study, progress with the ongoing global Phase 2/3 study, and amid the urgent need to address emerging viral strains
TEL AVIV, Israel and RALEIGH, NC, January 28, 2021, RedHill Biopharma Ltd. (Nasdaq: RDHL) ( RedHill or the Company ), a specialty biopharmaceutical company, today announced a manufacturing agreement with Cosmo Pharmaceuticals NV (SIX: COPN) ( Cosmo ) to further expand manufacturing capacity for opaganib (Yeliva®, ABC294640) , to address prospective demand subsequent to potential global emergency use authorizations. The growing concerns over viral mutations and the spread of new potent and evasive viral strains have increased the dire need for new COVID-19 therapeutics. said Reza Fathi, PhD., RedHill s Senior VP, R&D. We are very pleased to expand the manufacturing capacity of opaganib with a p
Analysis Demonstrates Effectiveness of LY-CoV555 Antibody in Preventing Symptomatic COVID-19
Analysis Demonstrates Effectiveness of LY-CoV555 Antibody in Preventing Symptomatic COVID-19
DURHAM, N.C., Jan. 25, 2021 Researchers from the COVID-19 Prevention Network (CoVPN) announced that the monoclonal antibody (mAb), LY-CoV555 (bamlanivimab), evaluated in a Phase III trial significantly reduces the risk of contracting symptomatic COVID-19 as well as reduces the clinical course of COVID-19 in study participants who did become symptomatic. The study, CoVPN 3501, was conducted in collaboration with Eli Lilly and Company in skilled nursing facilities (SNFs) across the United States. Residents and staff at SNFs participated in the trial.
A total of 1,097 participants (340 residents, 757 staff) were randomized to receive either a single 4,200 mg dose of LY-CoV555 or placebo (saline). Half of the study participants received LY-CoV555 and h
Кремль опубликовал содержание телефонного разговора Путина и Байдена rueconomics.ru - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from rueconomics.ru Daily Mail and Mail on Sunday newspapers.